Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

ACEP Clinical Policy on Intravenous Tissue Plasmogen for Stroke Continues to Evolve

By Ryan Patrick Radecki, MD, MS | on March 16, 2015 | 2 Comments
Pearls From the Medical Literature
  • Tweet
  • Email
Print-Friendly Version

ACEP Clinical Policy on Intravenous Tissue Plasmogen for Stroke Continues to Evolve

You Might Also Like
  • ACEP to Reconsider Clinical Policy on Use of Intravenous tPA to Manage Acute Ischemic Stroke in the ED
  • Clinical Policy on tPA for Ischemic Stroke Important for Emergency Medicine
  • ACEP Board Approves tPA Clinical Policy
Explore This Issue
ACEP Now: Vol 34 – No 03 – March 2015

In 2013, ACEP updated its clinical policy for the use of intravenous tissue plasminogen activator (tPA) for the management of acute ischemic stroke in the emergency department.1 This statement, eight years in the making, was published jointly by ACEP and the American Academy of Neurology (AAN) and endorsed by the Emergency Nurses Association and the Neurocritical Care Society.

Now it’s toast.

The ensuing outcry following its publication, followed by an ACEP Council resolution to reconsider the content, has led to a wholesale revision. Most important, even more than the proposed changes to this policy, were the changes to the clinical policy process, with improved adherence to rating methodology, an open comment period to draft policies, and improved management of conflict-of-interest (COI) issues. The last issue, management of COI, was a substantial source of prior controversy, covered in part by an investigative piece about untrustworthy guidelines in The BMJ.2 The authorship of this new version of the tPA policy has changed, and any association with the AAN is conspicuously absent.

The changes enshrined in this draft are substantial. The 2013 version made two recommendations regarding the use of IV tPA in the emergency department. The first, a Level A recommendation reflecting a high degree of clinical certainty, recommended tPA be offered to ischemic stroke patients meeting National Institute of Neurological Disorders and Stroke (NINDS) criteria who are treatable within 3 hours. The second, a Level B recommendation reflecting moderate clinical certainty, recommended tPA be offered to patients meeting European Cooperative Acute Stroke Study (ECASS) III criteria who are treatable between 3 and 4.5 hours. A caveat provided for this second recommendation noted the US Food and Drug Administration license for tPA is limited to 3 hours, with the subsequent application for extension having been rejected.

The changes enshrined in this draft are substantial. The 2013 version made two recommendations regarding the use of IV tPA in the emergency department.

Many emergency physicians felt these recommendations placed them in a difficult position by endorsing a treatment with significant adverse effects. While stroke neurologists and the American Heart Association forged ahead, with substantial contributions from Genentech, a vocal cohort of emergency physicians continued to express reservations and call for more data. In March 2014, the Australasian College for Emergency Medicine outlined a position statement indicating tPA was a potentially beneficial treatment for stroke but such treatment could not be considered a standard of care in light of conflicting evidence.3 Then, in September 2014, the UK Medicines and Healthcare Products Regulatory Agency reopened a review of the “balance of benefits and risks” of the use of tPA for stroke.4 Now this new tPA policy draft shifts ACEP in the same direction.

Pages: 1 2 3 | Single Page

Topics: ACEPAmerican College of Emergency PhysiciansClinical GuidelineCritical CareEmergency DepartmentEmergency MedicineNeurologyStroketPA

Related

  • EM Runs in the Family

    February 26, 2025 - 0 Comment
  • Navigating Strict State Abortion Laws

    January 5, 2025 - 1 Comment
  • Post-Tonsillectomy Hemorrhage: A Three-Pronged Approach

    January 5, 2025 - 3 Comments

Current Issue

ACEP Now May 03

Read More

About the Author

Ryan Patrick Radecki, MD, MS

Ryan Patrick Radecki, MD, MS, is an emergency physician and informatician with Christchurch Hospital in Christchurch, New Zealand. He is the Annals of Emergency Medicine podcast co-host and Journal Club editor and can be found on Twitter @emlitofnote.

View this author's posts »

2 Responses to “ACEP Clinical Policy on Intravenous Tissue Plasmogen for Stroke Continues to Evolve”

  1. March 18, 2015

    Brian S. Alper Reply

    For a detailed analysis of the evidence on t-PA 3-4.5 hours after stroke see BMJ 2015;350:h1075 published March 17 at http://www.bmj.com/content/350/bmj.h1075

    We shared this information during the draft guideline feedback period so hopefully it will be analyzed while the policy-making is in full swing — harder to adjust after formal publication.

    We also shared with CAEP (guideline in draft state with weak recommendation against) and MHRA (the UK drug regulating agency reconsidering drug licensing)

  2. May 18, 2015

    The tPA controversy | Sinai-Grace Emergency Medicine Residency Reply

    […] of ACEP Now (it’s that monthly newsletter that we all get and occasionally read). Here is the link. Essentially, the clinical guidelines recommending tPA are changing. They used to be level A […]

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603